Please login to the form below

Not currently logged in
Email:
Password:

Sanofi SVP to become president and CEO of Teva Europe

Dr Rob Koremans will take over from Dr Gerard van Odijk

Rob Koremans - Teva EuropeSenior vice president, generic strategy and development, at Sanofi, Dr Rob Koremans, has been appointed president and CEO of Teva Europe.

Koremans will begin his new position in March 2012, when he will take over from Dr Gerard van Odijk who has held both positions for six years.

Van Odijk will remain with the company for the rest of 2012 to help with the transition.

Shlomo Yanai, who is to step down from his current position of president and CEO of Teva Pharmaceutical in May, commented on the announcement.

He said: “Under [van Odijk's] management, our business in Europe has been transformed as Teva became the undisputed generics leader in this major and growing market and established a strong position in speciality pharmaceuticals.

“I am very confident that Rob Koremans, together with our strong European management, will continue our success story across Europe.”

Prior to his current position at Sanofi, Koremans was CEO at Zentiva, the European generics business for Sanofi.

He has also been CEO of Cryo-Save, the stem cell storage company, and was vice president, Europe, of the Serono Group.

4th January 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...